LIPC and hyperlipidemia: By administering atorvastatin and varying concentrations of fucoidan sulfate, the levels of HMG-CoA in the liver decreased, while the levels of HL, LPL, and LCAT increased compared to the model group, indicating the pharmaceutical effects of fucoidan on hyperlipidemia in a dose-dependent manner.